Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-00973-MS in Advanced Solid Tumors
NCT05673538Phase 1Not yet recruiting
- Sponsor
- TransThera Biosciences
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TT-00973-MS in solid tumor (advanced stage), sponsored by TransThera Biosciences. Primary endpoints: Incidence of Dose Limiting Toxicity and Incidence of adverse events and serious adverse events. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
TT-00973-MS
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05673538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673538.